Oct 31, 2018
Operational Update
Oct 23, 2018
Immutep Announces Data Presentations at Upcoming Industry Conferences
Oct 02, 2018
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Sep 26, 2018
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Sep 23, 2018
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
Sep 03, 2018
Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody
Aug 21, 2018
Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
Aug 15, 2018
Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
Aug 07, 2018
TACTI-mel Patient Recruitment Complete and Operational Update
Jul 30, 2018
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Jul 02, 2018
Immutep Submits Investigational New Drug (IND) Application with FDA
May 29, 2018
Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
